Related Experiment Video
Updated: Jun 17, 2025
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
[Risk-adapted early detection program for prostate cancer 2.0-position paper of the German Society of Urology 2024]
Maurice Stephan Michel1,2, Jürgen E Gschwend3, Bernd Wullich3
1Deutsche Gesellschaft für Urologie, Geschäftsstelle Berlin, Martin-Buber-Straße 10, 14163, Berlin, Deutschland. Maurice-Stephan.Michel@medma.uni-heidelberg.de.
Background And Objective:
Despite the proven effectiveness of organized PSA-based screening in reducing prostate cancer-related mortality, there is currently no program in Germany covered by statutory health insurance. In accordance with the EU Council Decision (2022/0290(NLE)), the German Society of Urology (DGU) has developed a concept for risk-adapted prostate cancer early detection.
Materials And Methods:
Based on a literature review of current screening studies, an algorithm for PSA-based prostate cancer early detection was developed.
Results:
Risk-adapted prostate cancer screening involves PSA testing in the age group of 45-70 years, followed by PSA-based individual risk stratification and stepwise expansion of diagnostics through magnetic resonance imaging (MRI) to biopsy. While initially up to 2.6 million men will undergo PSA testing, a reduction in these initial examinations to fewer than 200,000 men per year will occur from year four onwards.
Conclusions:
The presented algorithm provides clear recommendations for risk-adapted PSA-based early detection for prostate cancer for urologists and patients. The goal is to improve diagnosis of clinically significant prostate cancer, while reducing overdiagnosis and overtreatment.
